Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris 11:39:32 2024-04-25 am EDT After market 04:00:00 pm
91.62 EUR +4.47% Intraday chart for Sanofi 91.53 -0.10%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
SANOFI : DZ Bank reaffirms its Neutral rating ZD
European Equities Close Mostly Lower in Thursday Trading; BHP Bids Nearly $39 Billion to Acquire Anglo American MT
CAC40: manages to reduce losses at the end of the session CF
Global markets live: Ford, Dow, American Airlines, Comcast, Apple, IBM, Cisco... Our Logo
CAC40: losses trimmed, rates remain at their zenith CF
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading MT
CAC40: U.S. growth and inflation hold up, Nasdaq -2%. CF
SANOFI : Jefferies reiterates its Buy rating ZD
Sector Update: Health Care Stocks Lean Lower Pre-Bell Thursday MT
Dpa-AFX Overview: COMPANIES from 25.04.2024 - 15:15 DP
Transcript : Sanofi, Q1 2024 Earnings Call, Apr 25, 2024
SANOFI : Sanofi’s healthy Q1 performance hailed by markets Alphavalue
Sanofi Q1 Earnings Fall, Net Sales Climb MT
CAC40: down slightly on an avalanche of results CF
European Midday Briefing : Mood Cautious Ahead of More U.S Tech, Key Data DJ
Sanofi: quarterly EPS down by more than 7% at TCC CF
Wall Street: a note of weakness ahead of US GDP figures CF
Sanofi Posts Lower Q1 Net Income; Net Sales Up MT
Sanofi Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Sanofi Sales, Profit Beat Expectations DJ
Sanofi Q1 profit slips on generic competition, forex effects RE
EMEA Morning Briefing : Shares Seen Lower; Earnings, U.S. GDP Data in Focus DJ
SANOFI : Bernstein remains its Buy rating ZD
Sanofi to Enlist Banks for $20 Billion Consumer-health Spinoff MT
Sector Update: Health Care Stocks Rise Late Afternoon MT
Chart Sanofi
More charts
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
87.7 EUR
Average target price
107.7 EUR
Spread / Average Target
+22.77%
Consensus
  1. Stock Market
  2. Equities
  3. SAN Stock
  4. News Sanofi
  5. Sanofi : Closes $368 Million Purchase of Kiadis